Dr. Xiuqin Bao | Biology | Best Researcher Award

Guangdong Women and Children Hospital | China

Dr. Xiuqin Bao is a dedicated Associate Research Fellow specializing in medical genetics, with a strong background in epigenetic regulation and prenatal diagnostics. Her work focuses on developing innovative genetic therapies, particularly for blood disorders like β-thalassemia. She has co-authored multiple high-impact publications and contributed to significant research grants.

Professional profile👤

ORCID

Strengths for the Awards✨

• Strong Research Background:

  • Ph.D. in Genetics with a high GPA (3.8/4.0).

  • Focused research on β-thalassemia and γ-globin reactivation, a critical area in genetic medicine.

  • Published 8 papers, including multiple first/co-first author contributions in high-impact journals (IF 9.4–11.025).

• Innovative Contributions:

  • Developed CRISPR-Cas9 editing strategies for HBG2 promoter activation.

  • Identified DNA methylation biomarkers for γ-globin reactivation.

  • Co-invented a ddPCR-based assay for α-globin gene CNV detection (patent holder).

• Research Leadership & Funding:

  • Secured two major funded projects as Principal Investigator (total ¥350K).

  • Contributed to a ¥5.4M National Key R&D Program.

  • Recognized as Guangdong Outstanding Young Scholar (2024–2027).

• Clinical & Technical Expertise:

  • Handles 500+ clinical cases annually with a 99% diagnostic accuracy.

  • Expertise in CRISPR, omics, and bioinformatics.

Education 🎓

Dr. Bao earned her Ph.D. and M.S. in Genetics from Southern Medical University (2015–2020), where she investigated the epigenetic regulation of γ-globin reactivation in β-thalassemia. She also holds a B.S. in Biopharmaceuticals (2011–2015) and was recognized with multiple academic excellence awards, including the First-Class Academic Scholarship.

Experience 💼

Currently serving as a Clinical Laboratory Technologist at Guangdong Women and Children Hospital, Dr. Bao conducts advanced prenatal diagnostic testing for thalassemia. She previously led epigenetic research projects as a Doctoral Researcher at Southern Medical University, contributing to groundbreaking discoveries in DNA methylation biomarkers and CRISPR-Cas9 editing for γ-globin activation.

Research Interests On Biology 🔬

Dr. Bao’s primary research focus is on the genetic and epigenetic mechanisms underlying hereditary blood disorders. She is particularly interested in using CRISPR gene-editing technology to reactivate fetal hemoglobin, offering potential therapeutic strategies for β-thalassemia. Her work also extends to biomarker discovery for precision medicine applications.

Awards 🏆

Dr. Bao has received several prestigious awards, including:

• Guangdong Outstanding Young Scholar (2024–2027)
• First-Class Academic Scholarships (2016, 2017, 2022)
• Outstanding Communist Party Member (2018–2019) Her contributions to medical genetics have been recognized nationally and internationally.

Publications 📚

Dr. Bao has authored numerous high-impact publications, including:

• “Activation of γ-globin expression by LncRNA-mediated ERF promoter hypermethylation in β-thalassemia”​

  • Co-authors: Yuanyi Gao, Zhongju Wang, Yuhua Ye, Diyu Chen, Yangjin Zuo, Cunyou Zhao, Xiangmin Xu​

  • Publication Year: 2024​

• “DNA methylation patterns of β-globin cluster in β-thalassemia patients”​

  • Co-authors: Yangjin Zuo, Diyu Chen, Cunyou Zhao​

  • Publication Year: 2020​

  • Citations: 7​

• “Abnormal hemoglobin anti-Lepore Hong Kong compound with β⁰-thalassemia ameliorate thalassemia severity when co-inherited with α-thalassemia”​

  • Co-authors: Jicheng Wang, Danqing Qin, Cuize Yao, Jie Liang, Kailing Liang, Li Du​

  • Publication Year: 2024​

• “Severe fetal anemia and hydrops fetalis associated with compound heterozygosity for Hb Zurich-Albisrieden (HBA2:c.178G>C) and Hb Quong Sze (HBA2:c.377T>C)”​

  • Co-authors: Li Du, Wei He, Danqing Qin, Jicheng Wang, Ying Xiong, Xiaomei Shi, Hongke Ding, Cuize Yao, Jing Wu​

  • Publication Year: 2021​

• “Identification and characterization of CHD4-associated eRNA as a novel modulator of fetal hemoglobin levels in β-thalassemia”

  • Co-authors: Not specified​

  • Publication Year: 2024​

  • Citations: 1​

• “Two novel deletion mutations in β-globin gene cause β-thalassemia trait in two Chinese families”​

  • Co-authors: Danqing Qin, Jicheng Wang, Jing Chen, Cuize Yao, Jie Liang, Kailing Liang, Yixia Wang, Yousheng Wang, Li Du, Aihua Yin​

  • Publication Year: 2023​

• “Different effects of anxiety and avoidance dimensions of attachment on interpersonal trust: A multilevel meta-analysis”​

  • Co-authors: Song Li, Yaoyao Zhang, Qingting Tang, Xu Chen​

  • Publication Year: 2022​

Conclusion 📝

Dr. Xiuqin Bao is a leading researcher in medical genetics, whose work in epigenetic modulation and gene therapy holds great promise for the future of hereditary blood disorder treatments. Through her extensive research, publications, and clinical expertise, she continues to contribute significantly to the advancement of genetic medicine.